




Searching News Database: dyskinesia
HSMN NewsFeed - 17 Nov 2022
Upstaza(TM) Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA
Upstaza(TM) Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA
HSMN NewsFeed - 20 May 2022
PTC Therapeutics Receives Positive CHMP Opinion for Upstaza(TM) for the Treatment of AADC Deficiency
PTC Therapeutics Receives Positive CHMP Opinion for Upstaza(TM) for the Treatment of AADC Deficiency
HSMN NewsFeed - 2 May 2022
Supernus Announces FDA Approval of Qelbree(R) for the Treatment of ADHD in Adults
Supernus Announces FDA Approval of Qelbree(R) for the Treatment of ADHD in Adults
HSMN NewsFeed - 3 Nov 2021
Insightec Announces FDA Approval of Exablate Neuro for the Treatment of Parkinson's Disease
Insightec Announces FDA Approval of Exablate Neuro for the Treatment of Parkinson's Disease
HSMN NewsFeed - 27 Mar 2019
Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer
Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer
HSMN NewsFeed - 24 Apr 2018
Boston Scientific Announces Positive Late-Breaking Data From The INTREPID Study
Boston Scientific Announces Positive Late-Breaking Data From The INTREPID Study
HSMN NewsFeed - 11 Oct 2017
First Patient Treated With Titan Pharmaceuticals' Subdermal Implant For Parkinson's Disease
First Patient Treated With Titan Pharmaceuticals' Subdermal Implant For Parkinson's Disease
HSMN NewsFeed - 11 Apr 2017
Valeo Pharma and Zambon form partnership for Parkinson's Disease Treatment Xadago(R) (safinamide) in Canada
Valeo Pharma and Zambon form partnership for Parkinson's Disease Treatment Xadago(R) (safinamide) in Canada
HSMN NewsFeed - 28 Nov 2016
Addex Appoints Biopharmaceutical Industry Veteran, Roger G. Mills, M.D., as Chief Medical Officer
Addex Appoints Biopharmaceutical Industry Veteran, Roger G. Mills, M.D., as Chief Medical Officer
HSMN NewsFeed - 31 Aug 2016
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
HSMN NewsFeed - 23 May 2016
Zambon Launches Xadago(R) (Safinamide) in the U.K. for Patients with Mid- to Late-Stage Parkinson’s Disease
Zambon Launches Xadago(R) (Safinamide) in the U.K. for Patients with Mid- to Late-Stage Parkinson’s Disease
HSMN NewsFeed - 7 Mar 2016
Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health
Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health
HSMN NewsFeed - 12 Jan 2016
Zambon Launches Xadago(R) (Safinamide) in Switzerland for Patients with Parkinson’s Disease
Zambon Launches Xadago(R) (Safinamide) in Switzerland for Patients with Parkinson’s Disease
HSMN NewsFeed - 3 Nov 2015
Neurogastrx Appoints Baxter Phillips III as President and Chief Executive Officer
Neurogastrx Appoints Baxter Phillips III as President and Chief Executive Officer
HSMN NewsFeed - 15 May 2015
Zambon Launches Xadago(R) (safinamide) for Patients with Mid- to Late-Stage Parkinson’s Disease in Germany
Zambon Launches Xadago(R) (safinamide) for Patients with Mid- to Late-Stage Parkinson’s Disease in Germany
HSMN NewsFeed - 2 Dec 2013
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
HSMN NewsFeed - 23 Apr 2013
FDA Approves Second Drug in BD Simplist(TM) Prefilled Injectable Line of Products
FDA Approves Second Drug in BD Simplist(TM) Prefilled Injectable Line of Products
HSMN NewsFeed - 16 Jul 2012
UCB Launches Neupro(R) in the U.S. to Treat Parkinson’s Disease and Restless Legs Syndrome
UCB Launches Neupro(R) in the U.S. to Treat Parkinson’s Disease and Restless Legs Syndrome
HSMN NewsFeed - 3 Apr 2012
Neupro(R) Approved by U.S. FDA for Parkinson’s Disease and Restless Legs Syndrome
Neupro(R) Approved by U.S. FDA for Parkinson’s Disease and Restless Legs Syndrome
HSMN NewsFeed - 23 Apr 2010
UCB Receives Complete Response Letter from U.S. FDA Regarding Neupro(R) (Rotigotine)
UCB Receives Complete Response Letter from U.S. FDA Regarding Neupro(R) (Rotigotine)
HSMN NewsFeed - 23 Mar 2010
Once-Daily MIRAPEX ER Now Approved by FDA for Both Early and Advanced Parkinson's Disease
Once-Daily MIRAPEX ER Now Approved by FDA for Both Early and Advanced Parkinson's Disease
HSMN NewsFeed - 14 Dec 2009
FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
HSMN NewsFeed - 4 Dec 2009
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
HSMN NewsFeed - 14 Sep 2009
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
HSMN NewsFeed - 24 Aug 2009
Biovail to Acquire Rights to Develop, Commercialize JP-1730/Fipamezole in North America from Santhera
Biovail to Acquire Rights to Develop, Commercialize JP-1730/Fipamezole in North America from Santhera
HSMN NewsFeed - 29 May 2009
UCB receives CHMP positive opinion on bringing Neupro(R) back to all patients in Europe
UCB receives CHMP positive opinion on bringing Neupro(R) back to all patients in Europe
HSMN NewsFeed - 23 Mar 2009
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
HSMN NewsFeed - 23 Feb 2009
AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
HSMN NewsFeed - 15 Jan 2009
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
HSMN NewsFeed - 10 Oct 2008
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
HSMN NewsFeed - 14 May 2008
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
HSMN NewsFeed - 12 Mar 2008
Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
HSMN NewsFeed - 29 Feb 2008
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
HSMN NewsFeed - 13 Dec 2007
Neupro(R) Filed with the FDA for the Treatment of Advanced-Stage Parkinson's Disease
Neupro(R) Filed with the FDA for the Treatment of Advanced-Stage Parkinson's Disease
HSMN NewsFeed - 12 Dec 2007
INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
HSMN NewsFeed - 16 Nov 2007
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
HSMN NewsFeed - 28 Jun 2007
INVEGA(TM) Receives Marketing Authorization In European Union For Treatment Of Schizophrenia
INVEGA(TM) Receives Marketing Authorization In European Union For Treatment Of Schizophrenia
HSMN NewsFeed - 1 May 2007
CleveMed Receives FDA Clearance to Market Wireless Movement Disorder Monitor
CleveMed Receives FDA Clearance to Market Wireless Movement Disorder Monitor
HSMN NewsFeed - 27 Apr 2007
FDA Approves INVEGA (TM) for Long-Term Maintenance Treatment of Schizophrenia
FDA Approves INVEGA (TM) for Long-Term Maintenance Treatment of Schizophrenia
HSMN NewsFeed - 16 Apr 2007
SCHWARZ PHARMA Announces Publication of Rotigotine Data for Advanced Parkinson's Disease in Neurology
SCHWARZ PHARMA Announces Publication of Rotigotine Data for Advanced Parkinson's Disease in Neurology
HSMN NewsFeed - 13 Apr 2007
FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
HSMN NewsFeed - 30 Mar 2007
Study Suggests INVEGA(TM) Helps Patients With Schizophrenia Maintain Symptom Control
Study Suggests INVEGA(TM) Helps Patients With Schizophrenia Maintain Symptom Control
HSMN NewsFeed - 4 Jan 2007
Eli Lilly and Company Statement Regarding Today's New York Times Article - January 4, 2007
Eli Lilly and Company Statement Regarding Today's New York Times Article - January 4, 2007
HSMN NewsFeed - 4 Jan 2007
Lilly and Plaintiffs' Attorneys Enter Into Agreements to Settle Zyprexa(R) Product Liability Litigation
Lilly and Plaintiffs' Attorneys Enter Into Agreements to Settle Zyprexa(R) Product Liability Litigation
HSMN NewsFeed - 22 Dec 2006
Largest Disease Modification Trial for Parkinson's Disease Completes Enrollment
Largest Disease Modification Trial for Parkinson's Disease Completes Enrollment
HSMN NewsFeed - 20 Dec 2006
Alkermes Announces Submission of New Drug Application for RISPERDAL(R) CONSTA(R) in Japan
Alkermes Announces Submission of New Drug Application for RISPERDAL(R) CONSTA(R) in Japan
HSMN NewsFeed - 1 Dec 2006
Lilly Responds to the Cost-Effectiveness Analysis of the CATIE Schizophrenia Trial
Lilly Responds to the Cost-Effectiveness Analysis of the CATIE Schizophrenia Trial
HSMN NewsFeed - 28 Nov 2006
Neurogen In-licenses Drug Candidate for Parkinson's Disease and Restless Legs Syndrome
Neurogen In-licenses Drug Candidate for Parkinson's Disease and Restless Legs Syndrome
HSMN NewsFeed - 6 Oct 2006
FDA Approves RISPERDAL(R) for Treatment of Irritability Associated with Autistic Disorder
FDA Approves RISPERDAL(R) for Treatment of Irritability Associated with Autistic Disorder
HSMN NewsFeed - 18 Jul 2006
AstraZeneca Submits NDA for Sustained Release Formulation of SEROQUEL(R) for Schizophrenia Treatment
AstraZeneca Submits NDA for Sustained Release Formulation of SEROQUEL(R) for Schizophrenia Treatment
HSMN NewsFeed - 18 Jul 2006
Valeant Pharmaceuticals Announces Availability of Zelapar(R) for Parkinson's Disease Patients
Valeant Pharmaceuticals Announces Availability of Zelapar(R) for Parkinson's Disease Patients
HSMN NewsFeed - 12 Jul 2006
Teva Will Be Sole Promoter of AZILECT(R) for Parkinson's Disease in the United States
Teva Will Be Sole Promoter of AZILECT(R) for Parkinson's Disease in the United States
HSMN NewsFeed - 23 May 2006
New Study Suggests Symbyax(R) Significantly Improves Symptoms of Treatment-Resistant Depression
New Study Suggests Symbyax(R) Significantly Improves Symptoms of Treatment-Resistant Depression
HSMN NewsFeed - 22 May 2006
New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
HSMN NewsFeed - 17 May 2006
AZILECT(R) FDA Approval Brings New Hope to People Living With Parkinson's Disease
AZILECT(R) FDA Approval Brings New Hope to People Living With Parkinson's Disease
HSMN NewsFeed - 17 May 2006
Teva Announces FDA Grants Approval of AZILECT(R) (Rasagiline) for Parkinson's Disease
Teva Announces FDA Grants Approval of AZILECT(R) (Rasagiline) for Parkinson's Disease
Additional items found! 86

Members Archive contains
86 additional stories matching:
dyskinesia
(Password required)
dyskinesia
(Password required)